In August 2021, lower sodium oxybate (LXB) was the first treatment approved for idiopathic hypersomnia (IH). This is a breakthrough achievement; however, awareness and understanding of the new therapy, as well as other novel therapies, may be suboptimal. In data collected regarding LXB, only 8% of clinicians were aware LXB had received approval for IH pre-activity. In another pre-activity survey, 54% of clinicians were unlikely/not at all likely to use FDA-approved therapy in practice while 57% were unsure/not confident in transitioning patients from current therapy, suggesting a significant gap in knowledge regarding novel treatments. Clinicians need education on the clinically meaningful effects of LXB twice-nightly treatment for patients with IH.
In this CMEO Snack entitled, Ground Broken: Novel Therapies to Manage Idiopathic Hypersomnia, expert faculty will discuss current and novel therapies in IH, efficacy and safety data from recent clinical trials, and relevant findings from the SLEEP 2023 conference.
Utilize the latest efficacy and safety data to integrate novel therapies into clinical practice to mitigate the impact of IH.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Sleep specialists, primary care physicians, pulmonologists, neurologists, psychiatrists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Bogan reports the following financial relationships:
Consultant: Avadel; Axsome Therapeutics, Inc.; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; Oventus; and Takeda Pharmaceuticals U.S.A., Inc.
Research Support: Apnimed; Avadel; Bayer; Bresotec Medical; Eisai Inc.; Fisher Paykel Healthcare; FRESCA Medical; Idorsia Pharmaceuticals US Inc.; Jazz Pharmaceuticals, Inc.; LivaNova; Merck & Co., Inc.; NLS Pharmaceutics; Philips; Roche; Sanofi; Sommetrics, Inc.; Suven Pharma; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals Inc.
Speakers Bureau: Eisai Inc.; Harmony Biosciences; Idorsia Pharmaceuticals US Inc.; and Jazz Pharmaceuticals, Inc.
Dr. Morse reports the following financial relationships:
Advisory Board: Alkermes; Avadel; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Grants: Coverys Community Healthcare Foundation; Jazz Pharmaceuticals, Inc.; and ResMed Foundation
Research Support: Geisinger Health Plan; Jazz Pharmaceuticals, Inc.; and UCB, Inc.
Speakers Bureau: Jazz Pharmaceuticals, Inc.
Employment: DAMM Good Sleep, LLC (CEO)
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).